PE20081303A1 - Composicion farmaceutica que comprende un inhibidor de desacetilasa de histona y un antimetabolito - Google Patents
Composicion farmaceutica que comprende un inhibidor de desacetilasa de histona y un antimetabolitoInfo
- Publication number
- PE20081303A1 PE20081303A1 PE2007001696A PE2007001696A PE20081303A1 PE 20081303 A1 PE20081303 A1 PE 20081303A1 PE 2007001696 A PE2007001696 A PE 2007001696A PE 2007001696 A PE2007001696 A PE 2007001696A PE 20081303 A1 PE20081303 A1 PE 20081303A1
- Authority
- PE
- Peru
- Prior art keywords
- alkyl
- desacetilase
- histone
- pharmaceutical composition
- composition including
- Prior art date
Links
- 108010033040 Histones Proteins 0.000 title abstract 2
- 230000000340 anti-metabolite Effects 0.000 title abstract 2
- 229940100197 antimetabolite Drugs 0.000 title abstract 2
- 239000002256 antimetabolite Substances 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 102000003964 Histone deacetylase Human genes 0.000 abstract 2
- 108090000353 Histone deacetylase Proteins 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical class 0.000 abstract 2
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 abstract 1
- -1 AMINO Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE: (a) UNA HDAC (INHIBIDORES DE DESACETILASA DE HISTONA) DE FORMULA (I) DONDE R1 ES H, HALOGENO, ALQUILO C1-C6, ENTRE OTROS; R2 ES H, ALQUILO C1-C10, CICLOALQUILO C4-C9, ENTRE OTROS; R3 Y R4 SON CADA UNO H, ALQUILO C1-C6, ACILO, ACIL AMINO, ENTRE OTROS; R5 ES H, ALQUILO C1-C6, CICLOALQUILO C4-C9, ENTRE OTROS; n1, n2 Y n3 SON 0-6; X E Y SON CADA UNO H, HALOGENO, ALQUILO C1-C4, ENTRE OTROS; (b) UN ANTI-METABOLITO TAL COMO 5-AZACITIDINA. UN HDAC ES N-HIDROXI-3-[4-[[[2-(2-METIL-1H-INDOL-3-IL)-ETIL]-AMINO]-METIL]-FENIL]-2E-2-PROPENAMIDA. DICHA COMPOSICION ES UTIL EN EL TRATAMIENTO DE ENFERMEDADES PROLIFERATIVAS
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US86838806P | 2006-12-04 | 2006-12-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20081303A1 true PE20081303A1 (es) | 2008-10-28 |
Family
ID=39272127
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2007001696A PE20081303A1 (es) | 2006-12-04 | 2007-11-30 | Composicion farmaceutica que comprende un inhibidor de desacetilasa de histona y un antimetabolito |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US8093220B2 (es) |
| EP (1) | EP2099451B1 (es) |
| JP (3) | JP5784274B2 (es) |
| KR (1) | KR101475538B1 (es) |
| CN (1) | CN101553223A (es) |
| AR (1) | AR064072A1 (es) |
| AU (1) | AU2007328281B2 (es) |
| BR (1) | BRPI0719746A2 (es) |
| CA (1) | CA2670741C (es) |
| CL (1) | CL2007003467A1 (es) |
| EC (1) | ECSP099483A (es) |
| ES (1) | ES2569477T3 (es) |
| GT (1) | GT200900148A (es) |
| IL (1) | IL198638A (es) |
| MA (1) | MA30982B1 (es) |
| MX (1) | MX2009005946A (es) |
| MY (1) | MY148893A (es) |
| NO (1) | NO20092473L (es) |
| PE (1) | PE20081303A1 (es) |
| PL (1) | PL2099451T3 (es) |
| RU (1) | RU2469717C2 (es) |
| TN (1) | TN2009000213A1 (es) |
| TW (1) | TW200831075A (es) |
| WO (1) | WO2008070011A2 (es) |
| ZA (1) | ZA200903041B (es) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2519474T3 (es) | 2008-03-26 | 2014-11-07 | Novartis Ag | Inhibidores de las desacetilasas B basados en hidroxamato |
| BRPI0915927A2 (pt) * | 2008-07-18 | 2016-06-07 | Novartis Ag | uso de inibiodores de hdac para o tratamento da doença de hodgkin |
| WO2010009285A1 (en) * | 2008-07-18 | 2010-01-21 | Novartis Ag | Use of hdac inhibitors for the treatment of acute myeloid leukemia and/or myelodysplastic syndrome |
| US20110053925A1 (en) * | 2009-08-28 | 2011-03-03 | Novartis Ag | Hydroxamate-Based Inhibitors of Deacetylases |
| JP6031437B2 (ja) * | 2010-06-07 | 2016-11-24 | アブラクシス バイオサイエンス， エルエルシー | 増殖性疾患を処置するための組み合わせ療法 |
| CA2808908A1 (en) * | 2010-09-01 | 2012-03-08 | Novartis Ag | Combination of hdac inhibitors with thrombocytopenia drugs |
| CA2903473A1 (en) * | 2013-03-12 | 2014-10-09 | Quanticel Pharmaceuticals, Inc. | Histone demethylase inhibitors |
| JP2016538310A (ja) * | 2013-11-27 | 2016-12-08 | オンコエシックス ゲーエムベーハー | チエノトリアゾロジアゼピン化合物を含む医薬製剤を用いる白血病の治療方法 |
| AU2015318111A1 (en) | 2014-09-17 | 2017-04-13 | Celgene Quanticel Research, Inc. | Histone demethylase inhibitors |
| EP3932914A1 (en) | 2015-03-13 | 2022-01-05 | Valo Health, Inc. | Alpha-cinnamide compounds and compositions as hdac8 inhibitors |
| US10537585B2 (en) | 2017-12-18 | 2020-01-21 | Dexcel Pharma Technologies Ltd. | Compositions comprising dexamethasone |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20020354A1 (es) * | 2000-09-01 | 2002-06-12 | Novartis Ag | Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda) |
| US6905669B2 (en) * | 2001-04-24 | 2005-06-14 | Supergen, Inc. | Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase |
| CA2526908A1 (en) * | 2003-05-21 | 2004-12-02 | Novartis Ag | Combination of histone deacetylase inhibitors with chemotherapeutic agents |
-
2007
- 2007-11-30 CA CA2670741A patent/CA2670741C/en not_active Expired - Fee Related
- 2007-11-30 KR KR1020097013917A patent/KR101475538B1/ko not_active Expired - Fee Related
- 2007-11-30 AU AU2007328281A patent/AU2007328281B2/en not_active Ceased
- 2007-11-30 MX MX2009005946A patent/MX2009005946A/es active IP Right Grant
- 2007-11-30 US US12/516,656 patent/US8093220B2/en not_active Expired - Fee Related
- 2007-11-30 BR BRPI0719746-2A2A patent/BRPI0719746A2/pt not_active IP Right Cessation
- 2007-11-30 ES ES07862420.2T patent/ES2569477T3/es active Active
- 2007-11-30 JP JP2009540242A patent/JP5784274B2/ja not_active Expired - Fee Related
- 2007-11-30 WO PCT/US2007/024712 patent/WO2008070011A2/en not_active Ceased
- 2007-11-30 PL PL07862420T patent/PL2099451T3/pl unknown
- 2007-11-30 AR ARP070105351A patent/AR064072A1/es unknown
- 2007-11-30 CN CNA2007800429689A patent/CN101553223A/zh active Pending
- 2007-11-30 EP EP07862420.2A patent/EP2099451B1/en active Active
- 2007-11-30 MY MYPI20091975A patent/MY148893A/en unknown
- 2007-11-30 PE PE2007001696A patent/PE20081303A1/es not_active Application Discontinuation
- 2007-11-30 RU RU2009125439/15A patent/RU2469717C2/ru not_active IP Right Cessation
- 2007-12-03 TW TW096145961A patent/TW200831075A/zh unknown
- 2007-12-03 CL CL200703467A patent/CL2007003467A1/es unknown
-
2009
- 2009-05-04 ZA ZA200903041A patent/ZA200903041B/xx unknown
- 2009-05-07 IL IL198638A patent/IL198638A/en active IP Right Grant
- 2009-05-29 TN TNP2009000213A patent/TN2009000213A1/fr unknown
- 2009-06-03 GT GT200900148A patent/GT200900148A/es unknown
- 2009-06-10 MA MA31973A patent/MA30982B1/fr unknown
- 2009-06-30 NO NO20092473A patent/NO20092473L/no not_active Application Discontinuation
- 2009-07-03 EC EC2009009483A patent/ECSP099483A/es unknown
-
2013
- 2013-12-26 JP JP2013269307A patent/JP2014097992A/ja active Pending
-
2015
- 2015-07-21 JP JP2015144342A patent/JP2016006070A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20081303A1 (es) | Composicion farmaceutica que comprende un inhibidor de desacetilasa de histona y un antimetabolito | |
| ECSP099576A (es) | Combinación de lbh589 con otros agentes terapeuticos para | |
| PE20090641A1 (es) | Amidas heterociclicas | |
| MX2010005298A (es) | Compuestos de carboxamida, sulfonamida y amina para trastornos metabolicos. | |
| ECSP11010770A (es) | Compuesto heterocíclico y su uso | |
| ATE455110T1 (de) | 11-beta-hydroxysteroid-dehydrogenase-1-hemmer | |
| SV2009002865A (es) | Uso de oxazolidinonas para el tratamiento y profilaxis de microangiopatias | |
| EA201201050A1 (ru) | Пиразолы в качестве антагонистов crth2 | |
| ECSP12011880A (es) | INHIBIDORES DE N1-PIRAZOLOESPIROCETONA ACETIL-CoA CARBOXILASA | |
| EA201100037A1 (ru) | Органические соединения | |
| DK2021336T3 (da) | 11-beta-hydroxysteroid-dehydrogenase-1-inhibitorer | |
| BR112013030939A2 (pt) | derivado de indazol e pirrolopiridina e uso farmacêutico do mesmo | |
| PE20080061A1 (es) | Compuestos derivados de amida como inhibidores de los canales de potasio task-1 y task-3 | |
| PE20120561A1 (es) | Compuestos que modulan selectivamente el receptor cb2 | |
| EA201270590A1 (ru) | Ингибиторы акт | |
| EA200802382A1 (ru) | Соли n-гидрокси-3-[4-[[[2-(2-метил-1н-индол-3-ил)этил]амино]метил]фенил]-2е-2-пропенамида | |
| EA201170351A1 (ru) | Способы лечения невропатической боли | |
| EA201101621A1 (ru) | Производные бензоксазолона в качестве ингибиторов альдостеронсинтазы | |
| EA201300436A8 (ru) | Совместные кристаллы и соли ингибиторов ccr3 | |
| PE20081383A1 (es) | Inhibidores benzoimidazolicos de trpv1 | |
| DOP2009000139A (es) | Antagonistas nitroderivados del receptor de angiotensina ii | |
| PE20091847A1 (es) | Derivados de piridil-ptolinamida como antagonistas de receptores nk1 | |
| PE20080207A1 (es) | DERIVADOS DE 1-N-AMINO-2-IMIDAZOLIDINONAS COMO INHIBIDORES DEL CANAL DE POTASIO Kv1.5 | |
| JO3192B1 (ar) | مركب بنزوثيازولون | |
| PE20141353A1 (es) | Derivado de acido pirrolidin-3-ilacetico |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |